SRB2 is a humanized monoclonal antibody developed by SunRock Biopharma, S.L targeting CCR9.
🎯 This study demonstrates the efficacy of SRB2 through antibody-dependent cellular cytotoxicity (ADCC) in pancreatic cancer cells, as well as its activity in patient-derived organoids and xenograft models, achieving even complete tumor regression in a significant number of animals. These results support the further development of SRB2 as a promising therapeutic candidate for pancreatic cancer.
This work is the result of an excellent collaboration between the University of Kentucky, Universidade de Santiago de Compostela (CiMUS (Center for Research in Molecular Medicine and Chronic Diseases), and SunRock Biopharma. We are deeply grateful to all authors for their outstanding contribution. 🤝
🔗 Full article here: https://lnkd.in/dk3ZieTH
